Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24379098 | 0.82 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL24379427 | 0.82 | ADAM17 (0.47) | CRBNDDB1CYP19A1ADAM17 | |
| SCHEMBL24379146 | 0.80 | — | — | |
| SCHEMBL24379433 | 0.78 | DDB1 (0.42) | CRBNDDB1CYP19A1 | |
| SCHEMBL24379344 | 0.76 | CRBN (0.54) | CRBNDDB1CYP19A1 | |
| SCHEMBL24379428 | 0.75 | CRBN (0.39) | CRBNDDB1CYP19A1ADAM17 | |
| SCHEMBL24379429 | 0.75 | CRBN (0.37) | CRBNDDB1CYP19A1 | |
| SCHEMBL20128631 | 0.74 | CRBN (0.51) | CRBNDDB1 | |
| SCHEMBL20128632 | 0.74 | CRBN (0.51) | CRBNDDB1 | |
| SCHEMBL845542 | 0.74 | CRBN (0.51) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022098544-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220144809-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-05-12 | — | — | US | disclosed |
| WO-2022087125-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN | ARVINAS OPERATIONS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144809-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | AR, ADRM1, CRBN | CRBN 3/4885DDB1 409/4885CYP19A1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.